Inclusion Criteria:

1. Clinical Diagnosis of a flat keloid.

2. Age 18 to 50

3. A signed informed consent document (ICD)

4. Able and willing to receive bevacizumab

Women of child-bearing potential must have a negative pregnancy test during screening.
The effects of bevacizumab on the developing human fetus are unknown. For this reason
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. Should a woman become pregnant or suspect she is pregnant
while participating in this study, she should inform her treating physician immediately.

Exclusion Criteria:

1. Pedunculated Keloid

2. Diastolic Blood pressure of 90 mm Hg or above

3. History of any degree of Hypertension, even medically controlled hypertension

4. History of any form of cardiovascular disease or stroke

5. History of any form of thromboembolic event

6. History of renal dysfunction or proteinuria

7. History of recent (past 12 month) or planned (next 3 months) major surgery,

8. Men and women who plan to have children within 6 months of their last treatment

9. Psychological Illness that may result in non compliance with treatment

10. Pregnancy and Breast Feeding